TARSUS PHARMACEUTICALS, INC. Comprehensive Income
TARSUS PHARMACEUTICALS, INC. (TARS) reported Comprehensive Income of -$18.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$18.81M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$7.65M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$8.28M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$12.34M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$66.22M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$115.37M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$135.82M.
- TARSUS PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$62.16M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.81M 10-Q · filed 2026-08-06 | -$26.46M 10-Q · filed 2026-08-06 | -$34.74M derived: sum of 3 quarters · filed 2026-08-06 | -$47.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$7.65M 10-Q · filed 2026-05-06 | -$15.93M derived: sum of 2 quarters · filed 2026-05-06 | -$28.26M derived: sum of 3 quarters · filed 2026-05-06 | -$48.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$20.62M derived: sum of 2 quarters · filed 2026-02-23 | -$41.00M derived: sum of 3 quarters · filed 2026-08-06 | -$66.22M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$12.34M 10-Q · filed 2025-11-04 | -$32.72M derived: sum of 2 quarters · filed 2026-08-06 | -$57.94M 10-Q · filed 2025-11-04 | -$81.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$20.39M 10-Q · filed 2026-08-06 | -$45.60M 10-Q · filed 2026-08-06 | -$68.88M derived: sum of 3 quarters · filed 2026-08-06 | -$91.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$25.21M 10-Q · filed 2026-05-06 | -$48.49M derived: sum of 2 quarters · filed 2026-05-06 | -$71.39M derived: sum of 3 quarters · filed 2026-05-06 | -$104.80M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$23.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$46.18M derived: sum of 2 quarters · filed 2026-02-23 | -$79.58M derived: sum of 3 quarters · filed 2026-02-23 | -$115.37M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$22.90M 10-Q · filed 2025-11-04 | -$56.30M derived: sum of 2 quarters · filed 2025-11-04 | -$92.09M 10-Q · filed 2025-11-04 | -$133.99M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$33.40M 10-Q · filed 2025-08-06 | -$69.19M 10-Q · filed 2025-08-06 | -$111.09M derived: sum of 3 quarters · filed 2026-02-23 | -$150.22M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$35.79M 10-Q · filed 2025-05-01 | -$77.69M derived: sum of 2 quarters · filed 2026-02-23 | -$116.82M derived: sum of 3 quarters · filed 2026-02-23 | -$148.20M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$41.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$81.03M derived: sum of 2 quarters · filed 2026-02-23 | -$112.41M derived: sum of 3 quarters · filed 2026-02-23 | -$135.82M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$39.13M 10-Q · filed 2024-11-13 | -$70.51M derived: sum of 2 quarters · filed 2024-11-13 | -$93.92M 10-Q · filed 2024-11-13 | -$107.59M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$31.38M 10-Q · filed 2024-08-08 | -$54.79M 10-Q · filed 2024-08-08 | -$68.45M derived: sum of 3 quarters · filed 2025-02-25 | -$90.98M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$23.41M 10-Q · filed 2024-05-08 | -$37.08M derived: sum of 2 quarters · filed 2025-02-25 | -$59.60M derived: sum of 3 quarters · filed 2025-02-25 | -$65.34M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$13.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$36.18M derived: sum of 2 quarters · filed 2025-02-25 | -$41.93M derived: sum of 3 quarters · filed 2025-02-25 | -$62.16M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$22.52M 10-Q · filed 2023-11-09 | -$28.26M derived: sum of 2 quarters · filed 2023-11-09 | -$48.50M 10-Q · filed 2023-11-09 | -$63.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$5.74M 10-Q · filed 2023-08-10 | -$25.98M 10-Q · filed 2023-08-10 | -$40.83M derived: sum of 3 quarters · filed 2023-08-10 | -$56.53M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$20.24M 10-Q · filed 2023-05-09 | -$35.09M derived: sum of 2 quarters · filed 2023-05-09 | -$50.79M derived: sum of 3 quarters · filed 2023-05-09 | -$44.44M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$30.55M derived: sum of 2 quarters · filed 2023-03-17 | -$24.20M derived: sum of 3 quarters · filed 2023-03-17 | -$13.83M 10-K · filed 2023-03-17 |
| 2021-09-30 | -$15.70M 10-Q · filed 2022-11-09 | -$9.35M derived: sum of 2 quarters · filed 2022-11-09 | $1.02M 10-Q · filed 2022-11-09 | -$10.44M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $6.34M 10-Q · filed 2022-08-11 | $16.72M 10-Q · filed 2022-08-11 | $5.25M derived: sum of 3 quarters · filed 2022-08-11 | -$4.88M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $10.38M 10-Q · filed 2022-05-11 | -$1.09M derived: sum of 2 quarters · filed 2022-05-11 | -$11.23M derived: sum of 3 quarters · filed 2022-05-11 | -$14.48M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$21.61M derived: sum of 2 quarters · filed 2022-03-14 | -$24.86M derived: sum of 3 quarters · filed 2022-03-14 | -$26.81M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$10.14M 10-Q · filed 2021-11-10 | -$13.39M derived: sum of 2 quarters · filed 2021-11-10 | -$15.34M 10-Q · filed 2021-11-10 | -$16.76M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$3.25M 10-Q · filed 2021-08-05 | -$5.21M 10-Q · filed 2021-08-05 | -$6.62M derived: sum of 3 quarters · filed 2021-08-05 | -$7.30M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$1.96M 10-Q · filed 2021-05-11 | -$3.37M derived: sum of 2 quarters · filed 2021-05-11 | -$4.05M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$2.09M derived: sum of 2 quarters · filed 2021-03-31 | -$4.67M 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$681.00K 10-Q · filed 2020-11-25 | -$3.26M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |